Analyst Price Target is $4.00
▲ +374.27% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Histogen in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 374.27% upside from the last price of $0.84.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Histogen.
Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. It focuses in Human Multipotent Cell Conditioned Media, Human Extracellular Matrix, and Hair Stimulating Complex. The company was founded by Steven J. Mento and Gail K. Naughton on July 13, 2005 and is headquartered in San Diego, CA.